P-o-p Or P-s-p Containing (e.g., Anhydrides, Etc.) Patents (Class 514/106)
-
Patent number: 10759820Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.Type: GrantFiled: June 26, 2019Date of Patent: September 1, 2020Assignee: Ohio UniversityInventor: Rathindra N. Bose
-
Patent number: 10364264Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.Type: GrantFiled: May 24, 2017Date of Patent: July 30, 2019Assignee: Ohio UniversityInventor: Rathindra N. Bose
-
Patent number: 10143632Abstract: A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.Type: GrantFiled: November 13, 2014Date of Patent: December 4, 2018Assignee: The Procter and Gamble CompanyInventors: Jiten Odhavji Dihora, Mark Anthony Brown
-
Patent number: 9375497Abstract: The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.Type: GrantFiled: January 13, 2014Date of Patent: June 28, 2016Assignee: PIRAMAL IMAGING SAInventors: Ludger Dinkelborg, Matthias Friebe, Nikolaevna Raisa Krasikowa, Yuri Belokon, Fedorovna Olga Kuznetsova, Keith Graham, Lutz Lehmann, Mathias Berndt
-
Patent number: 9034820Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).Type: GrantFiled: March 13, 2012Date of Patent: May 19, 2015Inventor: Hsinyu Lee
-
Patent number: 9011822Abstract: A composition comprising iron pyrophosphate and copper citrate does not exhibit the unpleasant taste and aftertaste usually found with iron supplements.Type: GrantFiled: March 27, 2009Date of Patent: April 21, 2015Assignee: Bayer Consumer Care AGInventors: Marylène Fayet, Catherine Kabaradjian, Patrice Garcin
-
Publication number: 20150025041Abstract: Disclosed are methods of treating viral infections comprising, in one aspect, administering compounds that are phospholipase D inhibitors. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to antiviral therapies. For example, compounds having Phospholipase D activity (e.g., isoform selective Phospholipase D inhibitors) can be useful in antiviral therapies (e.g., influenza treatments).Type: ApplicationFiled: September 30, 2012Publication date: January 22, 2015Applicant: VANDERBILT UNIVERSITYInventors: Craig W. Lindsley, H. Alex Brown
-
Patent number: 8710032Abstract: Compounds and related methods as can be used for selective mevalonate pathway inhibitors.Type: GrantFiled: November 9, 2007Date of Patent: April 29, 2014Assignee: Northwestern UniversityInventors: Richard B. Silverman, Takashi Kudoh
-
Publication number: 20140100198Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: ApplicationFiled: December 12, 2013Publication date: April 10, 2014Applicant: The Board of Trustees of the University of IllinoisInventors: Eric Oldfield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Patent number: 8609638Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: GrantFiled: October 8, 2010Date of Patent: December 17, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Eric Oldfield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Publication number: 20130237503Abstract: The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Applicant: OHIO UNIVERSITYInventor: Rathindra N. Bose
-
Publication number: 20120288569Abstract: Phosphate depletion, a physiological condition commonly seen in certain patient populations, including alcoholics, malnourished, acutely ill patients, patients receiving parenteral nutrition, patients being re-fed after prolong fasting, and dialysis patients, requires intravenous supplementation when oral repletion is not feasible. This invention provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate, instead of phosphate, for phosphate or pyrophosphate repletion. During hemodialysis or peritoneal dialysis significant removal of phosphate and pyrophosphate occurs. Pyrophosphate depletion predisposes patients to vascular calcification. This invention further provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate or pyrophosphate repletion by addition of pyrophosphate to hemodialysis or peritoneal dialysis solutions.Type: ApplicationFiled: May 22, 2012Publication date: November 15, 2012Inventor: Ajay Gupta
-
Publication number: 20120270780Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).Type: ApplicationFiled: March 13, 2012Publication date: October 25, 2012Inventor: Hsinyu Lee
-
Patent number: 8236784Abstract: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.Type: GrantFiled: November 17, 2009Date of Patent: August 7, 2012Assignee: Sunny Biodiscovery, Inc.Inventors: Hui Zhao, Krzysztof Bojanowski, Fariba Aria, Reza Mortezaei
-
Publication number: 20120196835Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: ApplicationFiled: October 8, 2010Publication date: August 2, 2012Inventors: Eric Olafield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Patent number: 8232261Abstract: The present invention provides a method of reducing phytotoxicity or plant injury at a crop plant locus caused by a herbicide application at the locus which method includes applying to the crop plant locus a chloronicotinyl insecticide before the herbicide application.Type: GrantFiled: July 18, 2003Date of Patent: July 31, 2012Assignee: Bayer CropScience LPInventor: Michael R. Schwarz
-
Publication number: 20120178719Abstract: The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The present invention also relates to cell-based assays which may be used to identify agents that inhibit or reduce the activity of enzymes of the phospholipase D family and that may be used in the treatment of neurodegenerative diseases.Type: ApplicationFiled: November 28, 2011Publication date: July 12, 2012Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Gilbert DiPaolo, Tae-Wan Kim, Tiago Gil Oliveira
-
Publication number: 20120171286Abstract: Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further disclosed are kits containing a geranylgeranylation activator useful for the treatment of a statin-mediated myopathy.Type: ApplicationFiled: April 27, 2010Publication date: July 5, 2012Applicant: Beth Isreal Deaconess Medical CenterInventors: Vikas P. Sukhatme, Stewart H. Lecker, Jun-ichi Hanai
-
Publication number: 20120052026Abstract: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I).Type: ApplicationFiled: November 9, 2011Publication date: March 1, 2012Applicant: COLGATE-PALMOLIVE COMPANYInventors: Ravi Subramanyam, Prem Sreenivasan
-
Publication number: 20110293582Abstract: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.Type: ApplicationFiled: February 3, 2010Publication date: December 1, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Pulin Li
-
Patent number: 8022050Abstract: The present invention relates to a TRPA1 activation inhibitor, more precisely a TRPA1 activity inhibitor containing isopentenyl pyrophosphate and a method for inhibiting pain containing the step of administering isopentenyl pyrophosphate to a subject. Isopentenyl pyrophosphate of the present invention can regulate pain caused by TRPA1, so that it can be effectively used for the development of a pain inhibitor which is effective but has less side effects.Type: GrantFiled: February 18, 2009Date of Patent: September 20, 2011Assignee: Korea University Industry and Academic Collaboration FoundationInventors: Sun Wook Hwang, Sang-Soo Bang
-
Patent number: 8017596Abstract: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T ?9?2 lymphocyte activity and pharmaceutical compositions comprising them.Type: GrantFiled: January 14, 2010Date of Patent: September 13, 2011Assignee: Innate Pharma, S.A.Inventors: Jean-Louis Montero, Ibrahim Zgani, Chantal Menut, Valérie Gallois
-
Publication number: 20110178043Abstract: Compounds and related methods as can be used for selective mevalonate pathway inhibitors.Type: ApplicationFiled: November 9, 2007Publication date: July 21, 2011Inventors: Richard B. Silverman, Takashi Kudoh
-
Publication number: 20110112054Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: January 17, 2011Publication date: May 12, 2011Applicant: BIOAGENCY AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20110092465Abstract: The present invention involves pyrophosphate bridged coordination complexes and the treatment of medical conditions, such as cancer, using the pyrophosphate bridged coordination complexes. The pyrophosphate bridged coordination complexes include four new compounds, [Co(phen)2(H2P2O7)].4H2O (1.4H2O), [Ni(phen)2(H2P2O7)].8H2O (2.8H2O), [Cu(phen)(H2O)(H2P2O7)], and {[Cn(phen)(H2O)(P2O7)] [Na2(H2O)8]}.6H2O(4.14H2O) found effective for treating cancer cells. The pyrophosphate bridged coordination complexes also include three previously reported compounds, {[Ni(phen)2]2(?-P2O7)}.27H2O (compound 11), {[Cu(phen)(H2O)]2(?-P2O7)}.8H2O (compound 12), and {[Co(phen)2]2(?-25 P2O7)}.6MeOH (compound 13), (where phen is 1,1 0?-phenanthroline), whose effectiveness in treating cancer cells was previously unknown.Type: ApplicationFiled: October 21, 2010Publication date: April 21, 2011Applicant: SYRACUSE UNIVERSITYInventor: Robert Doyle
-
Publication number: 20100323990Abstract: The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.Type: ApplicationFiled: June 21, 2007Publication date: December 23, 2010Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond Andersen, Matthew Nodwell, Alice Mui
-
Publication number: 20100291185Abstract: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.Type: ApplicationFiled: November 17, 2009Publication date: November 18, 2010Applicant: SUNNY BIODISCOVERY, INC.Inventors: Hui Zhao, Krzysztof Bojanowski, Fariba Aria, Reza Mortezaei
-
Publication number: 20100254940Abstract: The present invention relates to compositions an methods for regulating an immune response in a subject, particularly to treat a subject with a tumor, notably a solid tumor, or an infectious disease. Disclosed are methods of regulating the innate immunity in a subject, such as by regulating the activity of ?? T cells in a subject. Disclosed are combinations of particular agents, such as a cytokine and a ?? T cell activator, particular administration regimens and dosages can produce a remarkable expansion of ?? T cells in vivo and a remarkable increase in a subject's immune defense. The invention can be used for therapeutic purposes, to produce, regulate or facilitate an immune response in a subject.Type: ApplicationFiled: June 28, 2010Publication date: October 7, 2010Applicant: INNATE PHARMA, S.A.Inventors: Francois Romagne, Helene Sicard, Jerome Tiollier, Christian Belmant
-
Publication number: 20100204184Abstract: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T ?9?2 lymphocyte activity and pharmaceutical compositions comprising them.Type: ApplicationFiled: January 14, 2010Publication date: August 12, 2010Applicants: LABORATOIRES MAYOLY SPINDLER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER IIInventors: Jean-Louis Montero, Ibrahim Zgani, Chantal Menut, Valérie Gallois
-
Patent number: 7709515Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: November 16, 2004Date of Patent: May 4, 2010Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Publication number: 20100068179Abstract: The invention provides compounds comprising at least one phosphohalohydrin group of the formula: where X is a halogen selected from among I, Br, Cl, R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, and n is an integer between 2 and 20, processes for the production thereof and uses theroef, in particular therapeutic uses and for activating primate T?9?2 lymphocytes.Type: ApplicationFiled: November 24, 2009Publication date: March 18, 2010Applicant: Institut National de la Sante et de la Recherche MedicaleInventors: Christian Belmant, Jean-Jacques Fournie, Marc Bonneville, Marie-Alix Peyrat
-
Publication number: 20100008865Abstract: A composition comprising iron pyrophosphate and copper citrate does not exhibit the unpleasant taste and aftertaste usually found with iron supplements.Type: ApplicationFiled: March 27, 2009Publication date: January 14, 2010Inventors: Maryléne Fayet, Catherine Kabaradjian, Patrice Garcin
-
Publication number: 20090306017Abstract: The present invention is directed towards a method of modulation of the innate immune of an organism system with the phosphorylated polyprenols of the present invention. The present invention is also directed towards a method of activation and/or modulation of the Toll-like Receptors with the phosphorylated polyprenols of the present invention. The present invention is also directed towards compound(s) comprising C35-C90 polyisoprenyls of Formula 1 and Formula 2 and their derivatives as well as methods of use of including activation and/or modulation of TLRs including TLR-2 and TLR-4 receptors and uses thereof including, e.g., use as antimicrobial, immunoregulatory, anti-cancer, cancer, for control of inflammatory conditions and as vaccine adjuvants.Type: ApplicationFiled: June 6, 2008Publication date: December 10, 2009Inventor: Tanya Kuritz
-
Publication number: 20090203648Abstract: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.Type: ApplicationFiled: April 14, 2009Publication date: August 13, 2009Applicants: Centre National de la Recherche Scientifique, Universite de Nantes, Institut National de la Sante et de la Recherche MedicaleInventors: Bruno Bujoli, Solen Josse, Jerome Guicheux, Pascal Janvier, Jean-Michel Bouler, Guy Daculsi
-
Publication number: 20090042838Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.Type: ApplicationFiled: August 6, 2008Publication date: February 12, 2009Applicant: Ohio UniversityInventor: Rathindra N. Bose
-
Publication number: 20090023686Abstract: A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.Type: ApplicationFiled: June 12, 2008Publication date: January 22, 2009Inventor: William S. McCall, JR.
-
Publication number: 20080300222Abstract: The invention provides novel phosphoantigen salts and novel crystalline phases of phosphoantigens salts, that the latter including non-solvated polymorphs, and solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, novel phosphoantigen crystalline phases. Methods of using such compositions for the treatment of disease, immunostimulatory or immune response modifying use are also provided. The invention also provides method for obtaining phosphoantigen crystals as well as highly pure phosphoantigen compositions.Type: ApplicationFiled: October 5, 2006Publication date: December 4, 2008Applicant: Innate PharmaInventors: Gerard Coquerel, Eric Aubin
-
Publication number: 20080249067Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: June 11, 2008Publication date: October 9, 2008Applicant: Bioagency AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Patent number: 7309698Abstract: Compounds and compositions for the delivery of bisphosphonates are provided. Methods of preparation, administration and treatment are provided as well.Type: GrantFiled: March 1, 2002Date of Patent: December 18, 2007Assignee: Emisphere Technologies, Inc.Inventors: Maria Aurora P. Boyd, Steve Dinh
-
Patent number: 7192940Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: July 16, 2004Date of Patent: March 20, 2007Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7101711Abstract: The invention provides compounds comprising at least one phosphoepoxide group of the formula: where R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate T?9?2 lymphocytes.Type: GrantFiled: August 27, 1999Date of Patent: September 5, 2006Assignee: Institut National de la Santa et de la Recherche MedicaleInventors: Christian Belmant, Jean-Jacques Fournie, Marc Bonneville, Marie-Alix Peyrat
-
Patent number: 7084126Abstract: Methods and composisions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds.Type: GrantFiled: April 27, 2001Date of Patent: August 1, 2006Assignee: HealthPartners Research FoundationInventors: William H. Frey, II, John Randall Fawcett
-
Publication number: 20040097436Abstract: Methods of treating a bacterial infection and of killing or inhibiting bacteria are disclosed. The methods use derivatives of triterpenes that are abundant in birch bark and other plants. The triterpenes include betulin, allobetulin, and lupeol.Type: ApplicationFiled: November 11, 2003Publication date: May 20, 2004Applicant: Regents of the University of MinnesotaInventors: Pavel A. Krasutsky, Robert M. Carlson, Raj Karim
-
Publication number: 20040087555Abstract: The invention provides compounds comprising at least one phosphohalohydrin group of the formula: 1Type: ApplicationFiled: October 14, 2003Publication date: May 6, 2004Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICATEInventors: Christian Belmant, Jean-Jacques Fournie, Marc Bonneville, Marie-Alix Peyrat
-
Patent number: 6589564Abstract: A method of treating solid neoplastic diseases is disclosed, which involves administering to a host in need of such treatment an effective amount of a pharmaceutically acceptable magnesium salt or complex, which can be a pharmaceutically acceptable inorganic magnesium salt such as magnesium pyrophosphate, or a pharmaceutically acceptable organic magnesium salt. The composition can be administered orally, parenterally, cutaneously or mucosally, and can be given, for example, in an amount of magnesium which is from 2 to 12 mg per kg of body weight daily. Preferred compositions include magnesium lactate, magnesium aspartate, magnesium acetate, and magnesium pyrophosphate. Neoplastic diseases amenable to the method include adenocarcinoma. The method can include administering with the magnesium salt or complex an effective amount of a pharmaceutically acceptable magnesium fixing substance, such as vitamin B6.Type: GrantFiled: May 11, 2001Date of Patent: July 8, 2003Inventor: Giampiero Valletta
-
Patent number: 6525035Abstract: The invention provides composition comprising, 1) polyprenol monophosphates of the formula H—[—CH2-C(CH3)═CH—CH2]n-O—P(═O)(OH)2 wherein n is an integer from 6-19 inclusive or a salt thereof, and 2) polyprenol pyrophosphates of the formula H—[—CH2-C(CH3)═CH—CH2]m—O—P(═O)(OH)—O—P(═O)(OH)2 wherein m is an integer from 6-19 inclusive or a salt thereof, which is useful as an antiviral agent, as an immunomodulatory agent, and for treating cancer. The invention also provides pharmaceutical compositions comprising the compositions of the invention as well as therapeutic methods for using the the compositions.Type: GrantFiled: June 10, 1999Date of Patent: February 25, 2003Assignee: Sass & Sass, Inc.Inventors: Leonid L. Danilov, Anna V. Deeva, Tanya Kuritz, Sergei D. Maltsev, Alexander N. Narovlianskiy, Alexander V. Pronin, Alexander V. Sanin, Olga Y. Sosnovskaya, Sergei V. Ozherelkov
-
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
Patent number: 6476006Abstract: The present invention provides compacted pharmaceutical composition for oral administration to a patient which expands upon contact with gastric fluid to retain a dosage form in the patient's stomach for an extended period of time, the formulation comprising a non-hydrated hydrogel, a superdisintegrant and tannic acid. The present invention further provides a pharmaceutical dosage form containing an active ingredient, and the compacted pharmaceutical composition. The invention further provides a dosage form suitable for delivering a therapeutic bis-phosphonate such as alendronate to the stomach of a patient over and extended period.Type: GrantFiled: January 26, 2001Date of Patent: November 5, 2002Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Moshe Flashner-Barak, Vered Rosenberger, Mazal Dahan, Yitzhak Lerner -
Patent number: 6008205Abstract: The present invention is directed to presqualene diphosphate (PSDP) analogs having an active region of natural PSDP and a metabolic transformation region resistant to rapid intracellular inactivation in vivo. For example, PSDP and its stable analogs can inhibit neutrophil signal transduction events in cellular activation that result in the generation of active oxygen species, regulation of leukocyte adherence, both homotypic (leukocyte-leukocyte) or heterotypic adherence with leukocytes and epithelial cells of mucosal origin or endothelial cells of vascular origin. These analogs can also be used to regulate leukocyte-dependent tissue injury.Type: GrantFiled: April 4, 1997Date of Patent: December 28, 1999Assignee: The Brigham & Women's Hospital, Inc.Inventors: Charles N. Serhan, Bruce D. Levy
-
Patent number: 5885973Abstract: The present invention provides methods for bone mass anabolic preservation or augmentation in human or other animal subjects affected by osteoporosis or other metabolic bone disorder characterized by systemic or regional bone loss, using bisphosphonates formulations, wherein the bone mass anabolic composition contains effective non-toxic doses of ?3-(N,N-dimethylamine)-1-hydroxypropylidene!-bisphosphonic acid or olpadronate or the monosodium or other pharmaceutically acceptable salt thereof.Type: GrantFiled: October 10, 1997Date of Patent: March 23, 1999Assignees: Gador, S.A., University of LeidenInventors: Socrates Papapoulos, Jose Luis Ferretti, Rafael A. Labriola, Nelida Mondelo, Emilio J.A. Roldan
-
Patent number: 5827838Abstract: The invention provides a method for inhibiting protein isoprenylation by administration of a polyisoprenyl pyrophosphate analogue. The polyisoprenyl pyrophosphate analogue may have formula 1, ##STR1## wherein: Pren represents a C.sub.10 -C.sub.30 terpenoid group or a derivative thereof;A.sup.1, A.sup.2, A.sup.3 and A.sup.4 independently represent a direct bond or a C.sub.1 -C.sub.4 alkylene or alkenylene group, optionally having substituents selected from methyl, hydroxy, methoxy, mercapto, methylthio, amino, methylamino, dimethylamino, halogen and a group having formula --X.sup.5 --A.sup.5 --P(.dbd.Z.sup.2)Y.sup.2 Y.sup.3 ; A.sup.5 represents a direct bond or a C.sub.1 -C.sub.4 alkylene or alkenylene group;X.sup.1, X.sup.2, X.sup.3, X.sup.4 and X.sup.5 independently represent a direct bond, oxygen, sulphur, imino or methylimino;Y.sup.1, Y.sup.2 and Y.sup.Type: GrantFiled: December 2, 1994Date of Patent: October 27, 1998Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno & Rijksuniversteit Te LeidenInventors: Louis Hartog Cohen, Jacobus Hubertus Van Boom, Gijsbert Arie Van Der Marel, Adrianus Petrus Robertus Marie Valentijn